Patents by Inventor Dung-Tsa Chen
Dung-Tsa Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230046649Abstract: The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion.Type: ApplicationFiled: July 29, 2022Publication date: February 16, 2023Inventors: Mokenge P. Malafa, Jennifer Permuth, Dung-Tsa Chen
-
Publication number: 20220356528Abstract: The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion.Type: ApplicationFiled: December 17, 2021Publication date: November 10, 2022Inventors: MOKENGE P. MALAFA, JENNIFER PERMUTH, DUNG-TSA CHEN
-
Publication number: 20200063215Abstract: The present invention concerns materials and methods for identifying and classifying pancreatic ductal adenocarcinoma (PDAC) precursors or intraductal papillary mucinous neoplasm (IPMN) using messenger RNAs, microRNAs, long non-coding RNAs, radiomic features, radiologic measures of abdominal/visceral obesity, and combinations thereof, as diagnostic markers for integration with clinical management and interventions for personalized care.Type: ApplicationFiled: May 3, 2018Publication date: February 27, 2020Inventors: JENNIFER PERMUTH, DANIEL JEONG, JUNG CHOI, YOGANAND BALAGURUNATHAN, DUNG-TSA CHEN, MOKENGE MALAFA
-
Publication number: 20190376143Abstract: The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion.Type: ApplicationFiled: March 23, 2019Publication date: December 12, 2019Inventors: MOKENGE P. MALAFA, JENNIFER PERMUTH, DUNG-TSA CHEN
-
Patent number: 10240208Abstract: The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion.Type: GrantFiled: March 31, 2015Date of Patent: March 26, 2019Assignee: H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.Inventors: Mokenge P. Malafa, Jennifer Permuth, Dung-Tsa Chen
-
Patent number: 10240206Abstract: Biomarkers, methods, assays, and kits are provided for predicting the efficacy of adjuvant chemotherapy (ACT) in a subject with early-stage non-small cell lung cancer (NSCLC).Type: GrantFiled: February 3, 2014Date of Patent: March 26, 2019Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: W. Douglas Cress, Dung-Tsa Chen
-
Publication number: 20170022571Abstract: The current invention pertains to miRNAs that are differentially expressed in samples of an individual having pancreatic cancer, or having a high risk of developing pancreatic cancer, as compared to the corresponding sample of an individual not having pancreatic cancer, or having low risk of developing pancreatic cancer, respectively. In certain embodiments, the miRNAs are differentially expressed in a tissue sample or blood plasma sample of an individual having a pancreatic lesion and having a high risk of developing pancreatic cancer as compared to the corresponding tissue sample or blood sample of an individual having the pancreatic lesion and having no risk or low risk of developing pancreatic cancer. These differentially expressed miRNAs can be used as biomarkers for diagnosis, treatment, and/or prevention of pancreatic cancer, particularly, in a subject having a pancreatic lesion.Type: ApplicationFiled: March 31, 2015Publication date: January 26, 2017Inventors: MOKENGE P. MALAFA, JENNIFER PERMUTH-WEY, DUNG-TSA CHEN
-
Patent number: 9528982Abstract: Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status.Type: GrantFiled: August 26, 2013Date of Patent: December 27, 2016Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan Lancaster, Douglas Marchion, Dung-Tsa Chen
-
Publication number: 20150376713Abstract: Biomarkers, methods, assays, and kits are provided for predicting the efficacy of adjuvant chemotherapy (ACT) in a subject with early-stage non-small cell lung cancer (NSCLC).Type: ApplicationFiled: February 3, 2014Publication date: December 31, 2015Inventors: Douglas W. Cress, Dung-Tsa Chen
-
Patent number: 9195796Abstract: The invention provides for malignancy-risk gene signatures that predict the risk of developing breast cancer, the recurrence of breast cancer, and/or the metastasis of breast cancer. These signatures have numerous clinical applications including assessing risk of breast cancer development following routine breast biopsy, assessing the need for adjuvant radiotherapy after lumpectomy, and determining the need for completion mastectomy following lumpectomy for the breast cancer patient and other treatment plans that are personalized for the patient.Type: GrantFiled: January 12, 2009Date of Patent: November 24, 2015Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Dung-Tsa Chen, Timothy J. Yeatman
-
Patent number: 9115388Abstract: Methods for predicting NF-kappaB (NF-kB) activity in a tumor, and more particularly to methods for predicting survival and therapeutic outcome, and selecting therapy in subjects with tumors, e.g., adenocarcinomas, e.g., lung adenocarcinomas and melanomas.Type: GrantFiled: November 1, 2012Date of Patent: August 25, 2015Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Amer A. Beg, Steven A. Enkemann, Dung-Tsa Chen
-
Patent number: 9063143Abstract: The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.Type: GrantFiled: December 22, 2010Date of Patent: June 23, 2015Assignees: University of South Florida, H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan Lancaster, Douglas C. Marchion, Dung-Tsa Chen
-
Publication number: 20140302060Abstract: Methods for predicting NF-kappaB (NF-kB) activity in a tumor, and more particularly to methods for predicting survival and therapeutic outcome, and selecting therapy in subjects with tumors, e.g., adenocarcinomas, e.g., lung adenocarcinomas and melanomas.Type: ApplicationFiled: November 1, 2012Publication date: October 9, 2014Applicant: H. Lee Moffitt Cancer and Research Institute, Inc.Inventors: Amer A. Beg, Steven A. Enkemann, Dung-Tsa Chen
-
Patent number: 8741575Abstract: The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.Type: GrantFiled: August 29, 2012Date of Patent: June 3, 2014Assignee: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Domenico Coppola, Dung-Tsa Chen, Steven Brem
-
Publication number: 20140017703Abstract: Despite initial sensitivity BAD-protein phosphorylation were evaluated in patient samples and cell lines as determinants of chemo-sensitivity and/or clinical outcome, and as therapeutic targets. Induced in-vitro OVCA cisplatin-resistance was associated with BAD-pathway expression. Expression of the pathway was also associated with resistance of 7 different cancers cell-types to 8 chemotherapeutic agents. Phosphorylation of the BAD-protein was associated with platinum-resistance in OVCA cells and primary OVCA specimens, and also overall patient survival. Targeted modulation of BAD-phosphorylation levels influenced cisplatin-sensitivity. A 47-gene BAD-pathway signature was associated in-vitro phospho-BAD levels and with survival of 838 patients with ovarian, breast, colon, and brain cancer. The survival advantage associated with both BAD-phosphorylation and also the BAD-pathway signature was independent of surgical cytoreductive status.Type: ApplicationFiled: August 26, 2013Publication date: January 16, 2014Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Johnathan Lancaster, Douglas Marchion, Dung-Tsa Chen
-
Publication number: 20130252831Abstract: A “malignancy-risk” (MR) gene signature score was developed with abundant proliferative genes using principal component analysis. This MR gene signature was shown to be a predictive and prognostic factor of overall survival in early-stage NSCLC. The malignancy-risk signature showed a significant association with OS, with poor survival seen in patients having a higher MR score and better survival seen in patients having a low MR score. As a prognostic factor, the MR gene signature showed a positive correlation with TNM stage, histologic grade, and smoking status. Combination of the MR signature with each clinical parameter often showed the best survival in the low MR group with good clinical outcome. The MR gene profile, tested with a PCA scoring method, discriminated overall survival in lung cancer patients was a predictor independent of pathological staging and other clinical parameters.Type: ApplicationFiled: May 10, 2013Publication date: September 26, 2013Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventor: Dung-Tsa Chen
-
Publication number: 20130011393Abstract: The invention provides materials and methods for prognosing cancer, and predicting an individual's responsiveness to cancer treatments, methods of treating cancer, and materials and methods for obtaining BAD pathway gene expression profiles useful in carrying out the methods of the invention.Type: ApplicationFiled: January 12, 2011Publication date: January 10, 2013Inventors: Johnathan Mark Lancaster, Dung-Tsa Chen, Yin Xiong
-
Publication number: 20120322687Abstract: The present invention relates to biomarkers for neoplasias such as high grade gliomas. The inventors have discovered that the overexpression of senescence associated genes (SAG) is associated with a poor prognosis in subjects with high grade gliomas. The present invention provides SAG biomarkers for predicting response to therapy for subjects having high grade glioma based on dividing the samples into high and low risk groups; diagnosing high grade glioma; monitoring progression of high grade glioma from one biological state to another; and determining efficacy of treatment for high grade gliomas.Type: ApplicationFiled: August 29, 2012Publication date: December 20, 2012Applicant: H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Domenico Coppola, Dung-Tsa Chen, Steven Brem
-
Publication number: 20110166095Abstract: The phosphorylation status of the BAD protein is a determinant of ovarian cancer cell responsiveness to platinum chemotherapy. Indirect manipulation of BAD phosphorylation status influences cisplatin sensitivity. BAD phosphorylation represents a biomarker that predicts platinum sensitivity and is a therapeutic target to increase platinum sensitivity. The methods employ phospho-specific antibody against a particular amino acid residue or site. Phospho-specific protein characterization methods include immunohistochemical (IHC), flow cytometric, immunofluorescent, capture-and-detection, or reversed phase assay.Type: ApplicationFiled: December 22, 2010Publication date: July 7, 2011Applicants: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Johnathan M. Lancaster, Douglas C. Marchion, Dung-Tsa Chen
-
Publication number: 20110046002Abstract: The invention provides a molecular marker set that can be used for prognosis of breast cancer in a patient using histologically normal tissue. The invention also provides methods for evaluating prognosis of breast cancer in a patient based on a molecular molecular signature.Type: ApplicationFiled: November 20, 2008Publication date: February 24, 2011Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Timothy Yeatman, Dung-Tsa Chen, Aejaz Nasir